Low-grade glioma pediatric · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Dabrafenib and Trametinib Variant #01 | — | R 52 791 | 28d | ~10.7 mo | — | ~13 | ~R 686 283 PFS proxy · indirect | 6 |
Carboplatin and Vincristine Variant #01 | — | R 9 687 | 70d | — | — | ~1 | ~R 9 687 indirect | — |
Temozolomide monotherapy Variant #02 | — | R 7 358 | 14d | ~4.0 mo | ~16.3 mo | ~26 | ~R 129 994 PFS proxy · indirect | 10 |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | ~5.0 mo | ~10.2 mo | ~4 | ~R 7 277 PFS proxy · indirect | 13 |
Tovorafenib monotherapy Variant #01 Partial | — | — | 7d | — | — | ~2 | — | — |
5 of 5 regimens shown